disease patients and have made a
long term commitment to the India
market. Our core therapeutic areas
are Hematology and Immunology.
We plan to expand therapeutic
area leadership by enhancing
commercial capabilities, increasing
global footprint and broadening
portfolio of best-in-class products.
Shire believes that people living
with rare diseases should have the
same access to treatment as those
with more prevalent conditions. We
want to be a champion and a voice
for patients in calling for equity of
access.
in India. Prior to this initiative,
there was no inclusion or mention
of rare diseases in the National
Health policy. The realities of
the current situation have to be
acknowledged and proper measures
need to be taken when it comes to
rare diseases. We feel very positive
about the government efforts to
create access to healthcare for all.
What are the primary product
offerings of Shire in India?
We are the champion for rare
How has the company
performed in the last
fiscal year? What are your
expectations in terms of
growth in the current FY?
In 2016, we took a big step forward
on our journey to become the
leading global biotech company
focused on rare diseases. We almost
doubled our annual revenue to $11
billion, increased our therapeutic
areas to seven, and quadrupled
our employees to approximately
24,000.
We continue to focus on
commercial execution and new
product launches, including
BIOVOICENEWS.COM
43